• Thane Wettig, CEO and director, reported the purchase of 2,800 Kyntra Bio common shares at USD 7.09.
• Direct holdings rose to 27,203 shares.
• The filing also listed 40 shares held indirectly by a spouse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001815638-26-000005), on May 18, 2026, and is solely responsible for the information contained therein.